Access to the PDF text

Free Article !

Archives of cardiovascular diseases
Volume 102, n° S1
pages 22-23 (mars 2009)
Doi : 10.1016/S1875-2136(09)72177-1
B006 Effects of losartan in an experimental model of metabolic syndrome

L. Fellmann, P. Bousquet
Laboratoire de Neurobiologie et Pharmacologie Cardiovasculaire, Inserm U715, Strasbourg, France 


A large body of experimental and clinical evidence indicates that some AT1 receptor antagonists may have beneficial metabolic effects in addition to their well-known cardiovascular actions. Whether or not these metabolic effects are related to additional PPARγ agonist activity of some AT1 antagonists is still under debate. Therefore, the aim of the present study was to check the cardiovascular and metabolic effects of losartan lacking any PPAR agonist activity in a suitable experimental model of metabolic syndrome, namely SHHF rats (Spontaneously Hypertensive, Heart Failure). These rats exhibit obesity, hypertension, dyslipidemia and glucose intolerance. They lack leptin receptors. WKY and SH rats were considered as control of SHHF rats.


Losartan was delivered in the drinking water (10mg/kg/day during 3 months) to 12-week-old male rats. Cardiovascular and metabolic parameters were measured at the end of the treatment and compared to those of untreated SHHF rats at the same age. Intravenous glucose tolerance tests (IVGTT) were also performed. Total cholesterol, LDL, HDL, triglycerides and glucose were measured on plasma samples (0,5ml) taken from caudal veins. Blood pressure was measured (right femoral artery) under pentobarbital anaesthesia (60mg/kg, ip).

Mean values±SEM are presented. P values < 0.05 were considered significant. Unpaired Student¡¦s t-tests were used for intergroup comparisons.


Effects of a 3-month treatment are shown in the previous table (SHHF rats).

* : p<0.05

Losartan impaired significantly glucose tolerance in SHHF rats.The treatment had no significant metabolic effect in WKY and SH rats.


Our study showed that, at an antihypertensive dose, losartan impaired glucose tolerance, fasted glycaemia, plasma triglycerides and free fatty acids in SHHF rats whereas it had no significant metabolic effect in WKY and SH rats.

The full text of this article is available in PDF format.
The full text of this article is available in PDF format.
Click here to see it.

© 2009  Elsevier Masson SAS. All Rights Reserved.
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Article Outline
You can move this window by clicking on the headline